Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma

Chimeric antigen receptor T cells (CAR-T cell) targeting CD19 are effective against several subtypes of CD19-expressing hematologic malignancies. Centralized manufacturing has allowed rapid expansion of this cellular therapy, but it may be associated with treatment delays due to the required logistics. We hypothesized that point of care manufacturing of CAR-T cells on the automated CliniMACS Prodigy® device allows reproducible and fast delivery of cells for the treatment of patients with non-Hodgkin lymphoma. Here we describe cell manufacturing results and characterize the phenotype and effector function of CAR-T cells used in a phase I/II study. We utilized a lentiviral vector delivering a second-generation CD19 CAR construct with 4-1BB costimulatory domain and TNFRSF19 transmembrane domain. Our data highlight the successful generation of CAR-T cells at numbers sufficient for all patients treated, a shortened duration of production from 12 to 8 days followed by fresh infusion into patients, and the detection of CAR-T cells in patient circulation up to 1-year post-infusion.

[1]  M. Perales,et al.  CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives , 2019, Leukemia.

[2]  R. Sékaly,et al.  Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells , 2019, Scientific Reports.

[3]  Yan Zhang,et al.  T Cell Dysfunction in Cancer Immunity and Immunotherapy , 2019, Front. Immunol..

[4]  Y. Zhang,et al.  Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects , 2019, Protein & Cell.

[5]  R. Orentas,et al.  CD19 CAR T cell product and disease attributes predict leukemia remission durability. , 2019, The Journal of clinical investigation.

[6]  Kimberly R. Jordan,et al.  Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system , 2018, Drug design, development and therapy.

[7]  Hans Bitter,et al.  Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell , 2018, Nature Medicine.

[8]  Leland McInnes,et al.  UMAP: Uniform Manifold Approximation and Projection , 2018, J. Open Source Softw..

[9]  S. Grupp,et al.  Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells , 2018, Cancer Immunology Research.

[10]  Hans Bitter,et al.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.

[11]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[12]  P. Hari,et al.  Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. , 2017, Cytotherapy.

[13]  U. Holtick,et al.  Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use. , 2017, Human gene therapy.

[14]  Ying Xiong,et al.  A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines , 2017, Journal of Immunotherapy for Cancer.

[15]  L. Arseniev,et al.  Automated Enrichment, Transduction, and Expansion of Clinical-Scale CD62L+ T Cells for Manufacturing of Gene Therapy Medicinal Products , 2016, Human gene therapy.

[16]  K. Peggs,et al.  Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. , 2016, Cytotherapy.

[17]  Christine E Brown,et al.  Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. , 2016, Blood.

[18]  Xiuyan Wang,et al.  Clinical manufacturing of CAR T cells: foundation of a promising therapy , 2016, Molecular therapy oncolytics.

[19]  I. Melero,et al.  Deciphering CD137 (4‐1BB) signaling in T‐cell costimulation for translation into successful cancer immunotherapy , 2016, European journal of immunology.

[20]  D. Maloney,et al.  Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo , 2015, Leukemia.

[21]  Sean C. Bendall,et al.  Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis , 2015, Cell.

[22]  M. Curran,et al.  4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity , 2015, Front. Oncol..

[23]  C. Cancrini,et al.  In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells , 2015, Science Translational Medicine.

[24]  Harjeet Singh,et al.  Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials , 2013, PloS one.

[25]  T. Waldmann,et al.  Superior T memory stem cell persistence supports long-lived T cell memory. , 2013, The Journal of clinical investigation.

[26]  S. Bicciato,et al.  IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. , 2013, Blood.

[27]  R. Morgan,et al.  Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry , 2012, Journal of Translational Medicine.

[28]  F. Marincola,et al.  A human memory T-cell subset with stem cell-like properties , 2011, Nature Medicine.

[29]  J. Harty,et al.  Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1. , 2010, Immunity.

[30]  Joonsoo Kang,et al.  Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8 T cell memory , 2010, Proceedings of the National Academy of Sciences.

[31]  P. Muranski,et al.  Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells , 2009, Nature Medicine.

[32]  R. Brentjens,et al.  Application of CAR T cells for the treatment of solid tumors. , 2019, Progress in molecular biology and translational science.

[33]  Lung-Ji Chang,et al.  Adoptive immunotherapy for B-cell malignancies using CD19-targeted chimeric antigen receptor T-cells: A systematic review of efficacy and safety. , 2017, Current medicinal chemistry.

[34]  A. Weinberg,et al.  The role of OX40-mediated co-stimulation in T-cell activation and survival. , 2009, Critical reviews in immunology.